In vitro drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 22, Issue 2, 2009, Pages 113-120

  Chambers, Frank ^a   Ludzik, Andrew ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Budesonide formoterol; Dose proportionality; Dose uniformity; Fine particle dose; Pressurized metered dose inhaler

Indexed keywords

BUDESONIDE PLUS FORMOTEROL;

AEROSOL; ARTICLE; AUTOMATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; IN VITRO STUDY; METERED DOSE INHALER; PARTICLE SIZE; PRESSURIZED METERED DOSE INHALER;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AEROSOLS; ANTI-ASTHMATIC AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; DRUG LABELING; EQUIPMENT DESIGN; ETHANOLAMINES; GLUCOCORTICOIDS; MATERIALS TESTING; METERED DOSE INHALERS; PARTICLE SIZE; PRESSURE;

EID: 67549144810     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2008.0697     Document Type: Article

References (16)

1. National Heart, Lung and Blood Institute, National Institutes of Health, US Department of Health and Human Services: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, Bethesda, MD, 2007. NIH publication 07-4051. http://www. nhlbi.nih.gov/ guidelines/asthma. Accessed January 7, 2008.
2. Corren J, Korenblat PE, Miller CJ, O'Brien CD, and Mez-zanotte WS: Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 2007;29:823-843.
3. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, and O'Dowd L: Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;66:2235-2254.
4. Inhalation Drug Products Working Group of the Chemistry, Manufacturing and Controls Committee: Guidance for Industry. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Center for Evaluation and Research, Rockville, MD, 1998. http://www.fda.gov/cder/guidance/ 2180dft.htm. Accessed January 7, 2008.
5. Nasr MM: Parametric tolerance interval test for delivered dose uniformity (DDU). Presented at: Advisory Committee of Pharmaceutical Science; October 25, 2005, 2005; Rockville, MD. http://www.fda.gov/ohrms/dockets/ac/05/slides/ 2005-4187S1-13-Nasr.ppt. Accessed January 7, 2008
6. United States Pharmacopeia: Delivered dose uniformity within general chapter <601> Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers - metereddose inhalers and dry powder inhalers. 2007.
7. Heyder J, Gebhart J, Rudolf G, Schiller CF, and Stahlhofen W: Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J Aerosol Sci. 1986;17:811-825.
8. Tarara TE, Hartman MS, Gill H, Kennedy AA, and Weers JG: Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm Res. 2004;21: 1607-1614.
9. Lewis DA, Ganderton D, Meakin BJ, and Brambilla G: Modulite: a simple solution to a difficult problem. Respiration 2005;72 (Suppl 1):3-5.
10. Leach CL, Davidson PJ, and Boudreau RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metereddose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-1353.
11. Nagel MW, Wiersema KJ, Bates SL, and Mitchell JP: Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-in-flammatory formulation delivered by pressurized metered dose inhaler. J Aerosol Med. 2002;15:427-433.
12. Cripps A, Riebe M, Schulze M, and Woodhouse R: Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000;94 (Suppl B):S3-S9.
13. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, and Barnes PJ: Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol. 2003;95:2106-2112.
14. Zanen P, Go LT, and Lammers JW: Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996;51:977-980.
15. Esposito-Festen JE, Zanen P, Tiddens HA, and Lammers JW: Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. Br J Clin Pharmacol. 2007;64: 328-334.
16. Shah SR, Peters SP, Gillen M, Martin P, O'Brien CD: Systemic bioavailability and long-term systemic effects of budesonide and formoterol pressurized metered-dose inhaler in asthma patients. Annals Allergy Asthma Immunol. 2008;100(Suppl):A29 (abstr P22).